摘要
目的探究富马酸伏诺拉生片联合兰索拉唑治疗胃食管反流性咽喉病的临床效果。方法选取江苏省苏州市第九人民医院2020年1月至2021年11月收治的82例胃食管反流性咽喉病患者作为研究对象,以电脑随机数字表法将其分为研究组和对照组,各41例。对照组予以兰索拉唑治疗,研究组予以富马酸伏诺拉生片联合兰索拉唑治疗。两组均于给药28 d后评估临床疗效、咽喉反流症状及胃肠激素、血清炎症因子水平,并记录两组不良反应发生情况。结果研究组临床疗效优于对照组(P<0.05)。治疗后,两组反流性疾病问卷(RDQ)评分、胃肠道影响量表(GIS)评分及肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、血管活性肠肽水平均低于治疗前,促胃液素水平高于治疗前(P<0.05)。治疗后,研究组RDQ、GIS评分及TNF-α、IL-1β、血管活性肠肽水平均低于对照组,促胃液素水平高于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论富马酸伏诺拉生片联合兰索拉唑治疗胃食管反流性咽喉病患者,临床疗效优越且安全性良好,值得推广。
Objective To explore the clinical efficacy of Fumarate Vorolasan Tablets combined with Lansoprazole in the treatment of gastroesopha-geal reflux pharyngo-laryngeal disease.Methods A total of 82 patients with gastroesopha-geal reflux pharyngo-laryngeal disease admitted to Suzhou Ninth People’s Hospital,Jiangsu Province from January 2020 to November 2021 were selected as the research objects.They were divided into study group and control group by computer random number method,with 41 cases in each group.The control group was treated with Lansoprazole,and the study group was treated with Fumarate Vorolasan Tablets combined with Lansoprazole.The clinical efficacy,symptoms of laryngopharyngeal reflux,gastrointestinal hormones,and serum inflammatory factors were evaluated at28 days after administration,and the incidence of adverse reactions in both groups was recorded.Results The clinical effect of the study group was better than that of the control group(P<0.05).After treatment,the reflux disease questionnaire(RDQ)score,gastrointestinal impact scale(GIS)score,and the levels of tumor necrosis factor-α(TNF-α),interleukin-1β(IL-1β),and vasoactive intestinal peptide in two groups were lower than those before treatment,and gastrin level was higher than before treatment(P<0.05).After treatment,RDQ,GIS score,and levels of TNF-α,IL-1β,and vasoactive intestinal peptide in the study group were lower than those in the control group,while gastrin level was higher than that in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Fumarate Vorolasan Tablets combined with Lansoprazole in the treatment of gastroesopha-geal reflux pharyngo-laryngeal disease patients,which has superior clinical efficacy and good safety,worthy of promotion.
作者
郑益
王文彬
单春燕
ZHENG Yi;WANG Wenbin;SHAN Chunyan(Department of Otolaryngology,Suzhou Ninth People’s Hospital,Jiangsu Province,Suzhou215200,China;Department of Otolaryngology,Suzhou Municipal Hospital,Jiangsu Province,Suzhou215200,China;Department of Otolaryngology,Suzhou City Wujiang Hospital of Traditional Chinese Medicine,Jiangsu Province,Suzhou215200,China)
出处
《中国医药导报》
CAS
2022年第24期103-106,共4页
China Medical Herald
基金
江苏省卫生计生委医学科研项目(H2018010)。
关键词
胃食管反流性咽喉病
富马酸伏诺拉生片
兰索拉唑
胃肠激素水平
咽喉反流症状
Gastroesopha-geal reflux pharyngo-laryngeal disease
Fumarate Vorolasan Tablets
Lansoprazole
Gastrointestinal hormone level
Symptoms of laryngopharyngeal reflux
